Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-006",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "claude-sonnet-4",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"Heat Shock Protein 70 Disaggregase Amplification\",\n      \"description\": \"Targeted upregulation of HSP70 family members (HSPA1A, HSPA8) with HSP40 co-chaperones to actively disaggregate pathological TDP-43 condensates\",\n      \"target_gene\": \"HSPA1A\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.8,\n        \"evidence_strength\": 0.7,\n        \"novelty\": 0.6,\n        \"feasibility\": 0.9,\n        \"therapeutic_potential\": 0.7,\n        \"druggability\": 1.0,\n        \"safety_profile\": 0.6,\n        \"competitive_landscape\": 0.8,\n        \"data_availability\": 0.8,\n        \"reproducibility\": 0.8\n      },\n      \"composite_score\": 0.76\n    },\n    {\n      \"title\": \"PARP1 Inhibition Therapy\",\n      \"description\": \"Use FDA-approved PARP1 inhibitors to prevent TDP-43 recruitment to DNA damage sites and reduce cytoplasmic mislocalization\",\n      \"target_gene\": \"PARP1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.4,\n        \"evidence_strength\": 0.5,\n        \"novelty\": 0.7,\n        \"feasibility\": 1.0,\n        \"therapeutic_potential\": 0.6,\n        \"druggability\": 1.0,\n        \"safety_profile\": 0.8,\n        \"competitive_landscape\": 0.9,\n        \"data_availability\": 0.9,\n        \"reproducibility\": 0.7\n      },\n      \"composite_score\": 0.71\n    },\n    {\n      \"title\": \"Arginine Methylation Enhancement Therapy\",\n      \"description\": \"Pharmacological enhancement of PRMT1/CARM1 activity to reduce TDP-43 RNA-binding avidity and prevent pathological phase separation\",\n      \"target_gene\": \"PRMT1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.6,\n        \"evidence_strength\": 0.6,\n        \"novelty\": 0.9,\n        \"feasibility\": 0.5,\n        \"therapeutic_potential\": 0.8,\n        \"druggability\": 0.6,\n        \"safety_profile\": 0.4,\n        \"competitive_landscape\": 0.9,\n        \"data_availability\": 0.6,\n        \"reproducibility\": 0.6\n      },\n      \"composite_score\": 0.65\n    },\n    {\n      \"title\": \"RNA Granule Nucleation Site Modulation\",\n      \"description\": \"Selective inhibition of G3BP1/G3BP2 to prevent TDP-43 recruitment to pathological stress granules\",\n      \"target_gene\": \"G3BP1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.7,\n        \"evidence_strength\": 0.6,\n        \"novelty\": 0.8,\n        \"feasibility\": 0.4,\n        \"therapeutic_potential\": 0.6,\n        \"druggability\": 0.4,\n        \"safety_profile\": 0.5,\n        \"competitive_landscape\": 0.8,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.6\n      },\n      \"composite_score\": 0.61\n    },\n    {\n      \"title\": \"Serine/Arginine-Rich Protein Kinase Modulation\",\n      \"description\": \"Modulation of SRPK1/CLK1 to alter splicing regulator phosphorylation and reduce TDP-43 multivalent RNA interactions\",\n      \"target_gene\": \"SRPK1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.5,\n        \"evidence_strength\": 0.4,\n        \"novelty\": 0.7,\n        \"feasibility\": 0.6,\n        \"therapeutic_potential\": 0.5,\n        \"druggability\": 0.7,\n        \"safety_profile\": 0.4,\n        \"competitive_landscape\": 0.7,\n        \"data_availability\": 0.5,\n        \"reproducibility\": 0.5\n      },\n      \"composite_score\": 0.55\n    },\n    {\n      \"title\": \"Low Complexity Domain Cross-Linking Inhibition\",\n      \"description\": \"Selective TGM2 inhibition to prevent TDP-43 cross-linking and maintain dynamic condensate properties\",\n      \"target_gene\": \"TGM2\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.4,\n        \"evidence_strength\": 0.3,\n        \"novelty\": 0.6,\n        \"feasibility\": 0.7,\n        \"therapeutic_potential\": 0.5,\n        \"druggability\": 0.8,\n        \"safety_profile\": 0.4,\n        \"competitive_landscape\": 0.8,\n        \"data_availability\": 0.4,\n        \"reproducibility\": 0.4\n      },\n      \"composite_score\": 0.53\n    },\n    {\n      \"title\": \"Glycine-Rich Domain Competitive Inhibition\",\n      \"description\": \"Engineered peptide mimetics to competitively inhibit TDP-43 intermolecular interactions through the glycine-rich domain\",\n      \"target_gene\": \"TARDBP\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.6,\n        \"evidence_strength\": 0.5,\n        \"novelty\": 0.8,\n        \"feasibility\": 0.2,\n        \"therapeutic_potential\": 0.7,\n        \"druggability\": 0.3,\n        \"safety_profile\": 0.6,\n        \"competitive_landscape\": 0.9,\n        \"data_availability\": 0.6,\n        \"reproducibility\": 0.5\n      },\n      \"composite_score\": 0.57\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"HSPA1A\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"HSP70\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"HSP70\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"protein_folding_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"participates_in\"\n    },\n    {\n      \"source_id\": \"protein_folding_pathway\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"ALS\",\n      \"target_type\": \"disease\",\n      \"relation\": \"dysregulated_in\"\n    },\n    {\n      \"source_id\": \"PARP1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"PARP1_protein\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"PARP1_protein\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"DNA_damage_response\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"mediates\"\n    },\n    {\n      \"source_id\": \"TARDBP\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"TDP-43\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"TDP-43\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"RNA_splicing_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"PRMT1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"arginine_methylation_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"catalyzes\"\n    },\n    {\n      \"source_id\": \"arginine_methylation_pathway\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"TDP-43\",\n      \"target_type\": \"protein\",\n      \"relation\": \"modifies\"\n    },\n    {\n      \"source_id\": \"G3BP1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"stress_granule_formation\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"nucleates\"\n    },\n    {\n      \"source_id\": \"stress_granule_formation\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"FTD\",\n      \"target_type\": \"disease\",\n      \"relation\": \"contributes_to\"\n    },\n    {\n      \"source_id\": \"SRPK1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"SR_protein_phosphorylation\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"mediates\"\n    },\n    {\n      \"source_id\": \"TGM2\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"protein_crosslinking_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"catalyzes\"\n    }\n  ],\n  \"synthesis_summary\": \"The synthesis reveals HSP70 enhancement therapy as the most promising therapeutic approach with a composite score of 0.76, driven by exceptional druggability (existing clinical compounds like arimoclomol), strong mechanistic plausibility, and manageable development risks. PARP1 inhibition emerges as the second-ranked option (0.71) despite lower mechanistic confidence, primarily due to immediate repurposing opportunities with FDA-approved compounds and established safety profiles. The arginine methylation approach ranks third (0.65) with high novelty but faces significant feasibility challenges requiring novel activator chemistry development. The analysis identified critical knowledge gaps, particularly the need for better understanding of off-target effects and disease stage dependencies across all approaches. The competitive landscape favors HSP70 and PARP1 strategies due to existing chemical matter and established development pathways, while the peptide-based glycine-rich domain approach faces insurmountable delivery challenges despite reasonable mechanistic rationale. The knowledge graph mapping reveals key therapeutic nodes connecting protein folding machinery (HSP70), DNA damage responses (PARP1), and RNA processing pathways (TDP-43, SRPK1) to ALS-FTD pathogenesis, suggesting potential for combination therapies targeting multiple pathways simultaneously.\"\n}\n```",
  "tokens_used": "2069",
  "persona_id": "persona-synthesizer"
}